Evidence map›Paper›PMID 42423496›Full record

ArticleThe European journal of neuroscience2026

Performance of a Personalized Smart Cueing Device to Detect Freezing of Gait in Parkinson's Disease.

Matthijs van der Laan, Erwin E H van Wegen, Jens A N Keijser, Sander A L M Minnoye, Rein van Zutven, Vincent de Groot, Marc B Rietberg, Jorik Nonnekes

Abstract read
In one paragraph

Article in The European journal of neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Matthijs van der LaanDepartment of Rehabilitation Medicine, Amsterdam UMC, Amsterdam, the Netherlands.ORCID 0009-0000-8979-5601
Erwin E H van WegenDepartment of Rehabilitation Medicine, Amsterdam UMC, Amsterdam, the Netherlands.
Jens A N KeijserCue2Walk International B.V, The Hague, the Netherlands.
Sander A L M MinnoyeCue2Walk International B.V, The Hague, the Netherlands.
Rein van ZutvenCue2Walk International B.V, The Hague, the Netherlands.
Vincent de GrootDepartment of Rehabilitation Medicine, Amsterdam UMC, Amsterdam, the Netherlands.
Marc B RietbergDepartment of Rehabilitation Medicine, Amsterdam UMC, Amsterdam, the Netherlands.
Jorik NonnekesDonders Institute for Brain, Cognition and Behaviour; Department of Rehabilitation; Centre of Expertise for Parkinson & Movement Disorders, Radboud University Medical Centre, Nijmegen, the Netherlands.

Funding

ZonMw 10310012210002
6 · The paper itself

Abstract

External cueing is a proven strategy to overcome freezing of gait (FoG) in Parkinson's disease (PD). However, manual activation of cueing is often too late and continuous cueing may be perceived as burdensome. Therefore, the Cue2walk, a medical device for FoG detection and provision of external cues, was developed. This study aimed to determine (1) the performance to detect FoG of the Cue2walk device and (2) the effect of personal optimization on its performance to detect FoG. Twenty-four people with PD and daily FoG completed a gait circuit including FoG-triggering tasks in their own home environment, while wearing a Cue2walk device to collect acceleration data. Two experienced independent raters rated the occurrence of FoG using video annotation. The data set of each participant was split into a training (60%) and test set (40%), obtaining an even distribution of FoG episodes. The training set was used to personalize the settings of the algorithm. The test set was subsequently used to assess the performance to detect FoG of the standard and personalized setting by calculating sensitivity, specificity, and latency (time between onset and detection of FoG). Sensitivity was 28.2% ± 31.6%, specificity was 96.0% ± 4.1%, and latency was 1.9 s ± 2.4 s on the test set with the standard settings. With personalized settings, sensitivity was 89.1% ± 14.8%, specificity was 93.3% ± 5.5%, and latency was 1.6 s ± 2.2 s. Sensitivity was significantly higher for the personalized settings (p < 0.001), while latency and specificity remained similar. The Cue2walk device showed good performance to detect FoG when using the personalized settings. The clinical effectiveness needs to be determined in future research.

Indexed as

CuesGait Disorders, NeurologicParkinson DiseaseAgedFemaleGaitHumansMaleMiddle Agedfreezing of gait detectionlatencyParkinson's diseasesensitivityspecificity

Identifiers

PMID42423496
PMCPMC13348497

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.